IRIS
MORABITO, FORTUNATO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.935
NA - Nord America 2.203
EU - Europa 1.028
SA - Sud America 831
AF - Africa 120
Continente sconosciuto - Info sul continente non disponibili 116
OC - Oceania 6
AN - Antartide 1
Totale 7.240
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.038
SG - Singapore 1.023
BR - Brasile 609
CN - Cina 592
IT - Italia 496
VN - Vietnam 487
HK - Hong Kong 237
BD - Bangladesh 185
DE - Germania 108
FR - Francia 108
AR - Argentina 75
KR - Corea 68
FI - Finlandia 66
IN - India 58
CA - Canada 56
MX - Messico 52
GB - Regno Unito 47
IQ - Iraq 46
EC - Ecuador 37
RU - Federazione Russa 37
ZA - Sudafrica 34
ID - Indonesia 32
CO - Colombia 30
NL - Olanda 30
PK - Pakistan 28
UA - Ucraina 25
AT - Austria 24
TR - Turchia 21
UZ - Uzbekistan 21
VE - Venezuela 21
PY - Paraguay 16
CL - Cile 15
MY - Malesia 15
DZ - Algeria 14
JP - Giappone 14
PL - Polonia 14
SA - Arabia Saudita 14
PH - Filippine 13
ES - Italia 12
NP - Nepal 12
PE - Perù 12
CR - Costa Rica 11
KE - Kenya 11
MA - Marocco 11
EG - Egitto 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
ET - Etiopia 9
JO - Giordania 9
JM - Giamaica 8
PA - Panama 8
UY - Uruguay 8
BO - Bolivia 7
KG - Kirghizistan 7
BG - Bulgaria 6
CZ - Repubblica Ceca 6
NI - Nicaragua 6
SN - Senegal 6
TT - Trinidad e Tobago 6
DO - Repubblica Dominicana 5
HN - Honduras 5
IL - Israele 5
OM - Oman 5
RO - Romania 5
SE - Svezia 5
AL - Albania 4
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
CH - Svizzera 4
KZ - Kazakistan 4
RS - Serbia 4
AU - Australia 3
BE - Belgio 3
GT - Guatemala 3
IE - Irlanda 3
LB - Libano 3
LY - Libia 3
PS - Palestinian Territory 3
SC - Seychelles 3
TH - Thailandia 3
TW - Taiwan 3
AM - Armenia 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
DK - Danimarca 2
GA - Gabon 2
LT - Lituania 2
MK - Macedonia 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
QA - Qatar 2
SV - El Salvador 2
AQ - Antartide 1
BB - Barbados 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
CI - Costa d'Avorio 1
GY - Guiana 1
Totale 7.105
Salva come PNG Salva come JPEG
Città #
Singapore 433
San Jose 295
Council Bluffs 270
Ashburn 262
Dallas 236
Hong Kong 236
Ho Chi Minh City 170
Florence 155
Boardman 143
Beijing 112
Hefei 112
Hanoi 102
Seoul 67
Lauterbourg 65
São Paulo 64
Los Angeles 56
New York 52
Munich 48
Milan 47
Santa Clara 47
Shanghai 47
Helsinki 43
Rome 27
Da Nang 26
Rio de Janeiro 25
Haiphong 24
Sesto Fiorentino 23
Noto 22
Quito 21
Baghdad 20
Washington 20
Guangzhou 19
Montreal 18
Chicago 17
Tashkent 17
Mexico City 15
The Dalles 15
Brooklyn 14
Phoenix 14
Buffalo 13
Orem 13
Vienna 13
Bari 12
Johannesburg 12
Naples 12
Turku 12
Amsterdam 11
Atlanta 11
Biên Hòa 11
Catania 11
Guayaquil 11
Nairobi 11
Ogden 11
Omaha 11
Tokyo 11
Warsaw 11
Brasília 10
Caracas 10
Frankfurt am Main 10
Lappeenranta 10
Nuremberg 10
Addis Ababa 9
Amman 9
Belo Horizonte 9
Charlotte 9
Dhaka 9
Hillsboro 9
Karachi 9
Kuala Lumpur 9
Lahore 9
Mumbai 9
Ninh Bình 9
Ribeirão Preto 9
Thái Nguyên 9
Turin 9
Wuhan 9
Boston 8
Chennai 8
Fortaleza 8
London 8
Medellín 8
Portland 8
San José 8
Buenos Aires 7
Campinas 7
Can Tho 7
Hangzhou 7
Naaldwijk 7
New Delhi 7
Paris 7
San Francisco 7
Toronto 7
Bishkek 6
Bogotá 6
Brescia 6
Cape Town 6
Curitiba 6
Dakar 6
Denver 6
Duhok 6
Totale 3.948
Salva come PNG Salva come JPEG
Nome #
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 182
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 162
Vaccination in Multiple Myeloma: Challenges and Strategies 144
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 142
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 132
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 131
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 129
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 129
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 128
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 126
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 126
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 124
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 119
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 118
The role of corticosteroids in the current treatment paradigm for myelofibrosis 118
Momelotinib in myelofibrosis 118
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 114
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 114
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 113
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 113
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 112
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 111
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 110
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 109
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 109
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 107
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 106
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 100
Iron chelation therapy 100
Belantamab mafodotin in multiple myeloma 100
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 95
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 95
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 95
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 95
Selinexor in multiple myeloma 94
Teclistamab-cqyv in multiple myeloma 94
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 93
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 92
Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma 92
Acalabrutinib in chronic lymphocytic leukemia 92
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 92
Myelodysplastic syndromes with ring sideroblasts 91
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 89
Elotuzumab in multiple myeloma 88
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 86
Ivosidenib in acute myeloid leukemia 84
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 84
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 83
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 82
Avatrombopag for the Treatment of Immune Thrombocytopenia 80
Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study 76
Glasdegib for the treatment of acute myeloid leukemia 72
Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs 72
Therapy‐Related Acute Promyelocytic Leukemia: Case Series and Current Insights 71
Zanubrutinib for the treatment of chronic lymphocytic leukemia 71
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity 71
REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA 71
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 70
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 68
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 67
Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions 67
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia 62
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 61
Mosunetuzumab for the treatment of follicular lymphoma 61
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 58
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 57
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents 53
Venetoclax in acute myeloid leukemia 51
Isatuximab in multiple myeloma 50
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 49
T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions 46
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 45
Real‐World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia 35
Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy 35
Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies 30
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort 26
Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy 26
Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs 22
Reshaping multiple myeloma treatment: recent breakthroughs 21
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies 21
Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials 20
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction 19
Targeting the Menin– KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation 19
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration 18
Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions 15
Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM 13
Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 13
Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort 13
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives 11
Regional Standardization of CLL Management: Results of a Delphi Consensus Process 9
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies 9
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia 9
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management 8
To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy 7
Gut Microbiota and Acute Myeloid Leukemia: State of the Art, Clinical Signals, and Translational Opportunities 7
What Does It Really Mean to Say That a Patient With a Hematologic Malignancy Is “Cured”? 6
First‐Line Treatment of IGHV ‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens 6
The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities 6
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort 5
Totale 7.240
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.149
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.149
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202368 0 0 0 0 0 0 30 3 4 4 21 6
2023/2024593 9 14 121 90 53 90 29 20 20 9 21 117
2024/20251.380 53 107 33 72 66 63 32 67 202 138 139 408
2025/20264.703 485 260 409 314 726 316 524 221 387 444 311 306
2026/2027496 344 152 0 0 0 0 0 0 0 0 0 0
Totale 7.240